https://elixirgentx.com/news/ 2026-06-26T10:44:35+00:00 https://elixirgentx.com/elixirgen-therapeutics-successfully-concludes-pre-ind-meeting-with-fda/ 2017-05-30T16:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-llc-now-elixirgen-therapeutics-inc/ 2018-05-07T16:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-inc-raises-4-million-in-series-a-funds/ 2018-07-09T16:00:00+00:00 https://elixirgentx.com/fda-approves-elixirgen-therapeutics-ind-application-for-therapy-for-telomere-biology-disorders-with-bone-marrow-failure/ 2020-06-04T16:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-concludes-pre-ind-meeting-with-fda-for-its-covid-19-vaccine-candidate-exg-5003/ 2020-06-04T16:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-planning-to-begin-phase-i-ii-clinical-trials-of-its-covid-19-vaccine-candidate-exg-5003-at-fujita-health-university/ 2020-09-01T16:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-announces-dosing-of-first-and-second-participants-in-its-covid-19-vaccine-phase-1-2-clinical-trial-at-fujita-health-university/ 2021-05-25T16:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-announces-licensing-agreement-for-its-novel-covid-19-vaccine/ 2021-10-08T16:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-partners-with-taisho-pharmaceutical-on-therapeutics-for-aging-associated-diseases/ 2022-03-07T17:00:00+00:00 https://elixirgentx.com/controllable-self-replicating-rna-vaccine-delivered-intradermally-elicits-cellular-immunity-preprint-manuscript-posted/ 2022-09-07T16:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-to-present-new-data-showing-successful-ex-vivo-telomere-elongation-with-exg-34217-in-a-phase-1-2-clinical-trial-at-the-64th-ash-annual-meeting/ 2022-11-07T17:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-presents-new-clinical-data-demonstrating-ex-vivo-telomere-elongation-with-exg-34217-in-dyskeratosis-congenita-at-the-64th-ash-annual-meeting/ 2022-12-12T17:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-appoints-jeffrey-l-cleland-ph-d-to-board-of-directors/ 2022-12-21T17:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-to-attend-the-2023-biotech-showcase-conference/ 2023-01-05T01:12:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-enters-memorandum-of-understanding-with-hitachi-global-life-solutions-for-the-development-of-micro-gmp-suites-for-cell-therapy-administration/ 2023-01-26T13:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-announces-promising-phase-1-2-data-on-exg-5003-a-controllable-self-replicating-rna-c-srrna-vaccine-against-sars-cov-2/ 2023-10-16T14:24:46+00:00 https://elixirgentx.com/elixirgen-therapeutics-presents-preclinical-data-with-bobcat-mrnatm-technology-in-duchenne-muscular-dystrophy-at-the-2024-muscular-dystrophy-association-mda-clinical-scientific-conference/ 2024-03-04T13:12:28+00:00 https://elixirgentx.com/elixirgen-therapeutics-receives-rare-pediatric-disease-designation-for-exg-34217-in-dyskeratosis-congenita-and-related-telomere-biology-disorders/ 2024-09-25T12:00:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-exg-34217-for-treatment-of-telomere-biology-disorders/ 2025-02-13T13:30:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-granted-fda-orphan-drug-designation-for-exg-34217-for-treatment-of-telomere-biology-disorders/ 2025-02-20T21:05:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-publishes-early-results-showing-telomere-elongation-in-first-gene-therapy-trial-for-telomere-biology-disorders/ 2025-02-25T14:35:00+00:00 https://elixirgentx.com/elixirgen-therapeutics-and-nippon-shinyaku-enter-into-an-option-agreement-for-the-development-and-commercialization-of-exg-7001-for-duchenne-muscular-dystrophy/ 2026-06-26T10:44:35+00:00